{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:40:48Z","timestamp":1794256848255,"version":"4.9.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>Anti-HER2 therapy has recently emerged as an effective targeted treatment approach for patients with advanced stage and recurrent endometrial serous carcinoma, resulting in significantly prolonged progression-free and overall survival when combined with the standard chemotherapy regimen. Consequently, there is an increasing clinical demand in pathology laboratories for HER2 testing of these tumors. This article provides an overview of the unique characteristics of HER2 protein expression and gene amplification in endometrial serous carcinoma and summarizes the HER2 scoring criteria used for patient enrollment in the recent clinical trial. Following the experience of guideline-development in other tumor types, the trial criteria should serve as the basis for future endometrial carcinoma-specific HER2 testing and scoring recommendations, to ensure therapeutic response in new patient cohorts. Thus, based on the clinical trial, the author proposes a specific HER2 testing algorithm for endometrial serous carcinoma to guide the current clinical practice. Future studies are necessary to refine and adjust these criteria to allow for appropriate triaging of patients and maximize the clinical benefit from HER2-targeted therapy.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000711","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T04:00:32Z","timestamp":1607313632000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":68,"title":["HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting"],"prefix":"10.1097","volume":"40","author":[{"given":"Natalia","family":"Buza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,8]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ygyno.2008.11.014","article-title":"A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study","volume":"112","author":"Homesley","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ygyno.2018.02.022","article-title":"Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy","volume":"149","author":"Tortorella","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R5-20250802","first-page":"293","article-title":"Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer","volume":"21","author":"Menderes","year":"2016","journal-title":"Discov Med"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drup.2017.02.002","article-title":"Drug-biomarker co-development in oncology\u201420 years and counting","volume":"30","author":"Twomey","year":"2017","journal-title":"Drug Resist Updat"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R9-20250802","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2559.2009.03464.x","article-title":"HER-2\/neu receptor gene status in endometrial carcinomas: a tissue microarray study","volume":"56","author":"Xu","year":"2010","journal-title":"Histopathology"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","article-title":"Determination of HER2\/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization","volume":"98","author":"Santin","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","article-title":"HER-2\/neu amplification and overexpression in endometrial carcinoma","volume":"18","author":"Rolitsky","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"R14-20250802","first-page":"823","article-title":"Identification of HER-2\/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma","volume":"10","author":"Riben","year":"1997","journal-title":"Mod Pathol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1349-7006.2012.02240.x","article-title":"Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma","volume":"103","author":"Togami","year":"2012","journal-title":"Cancer Sci"},{"key":"R16-20250802","first-page":"122","article-title":"Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium","volume":"22","author":"Halperin","year":"2001","journal-title":"Eur J Gynaecol Oncol"},{"key":"R17-20250802","first-page":"1271","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2005.08.017","article-title":"Clinical significance of Her-2\/neu overexpression in uterine serous carcinoma","volume":"100","author":"Diaz-Montes","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/gyno.1994.1092","article-title":"Expression of EGFR, HER-2\/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas","volume":"53","author":"Khalifa","year":"1994","journal-title":"Gynecol Oncol"},{"key":"R20-20250802","first-page":"5693","article-title":"Amplification and overexpression of HER-2\/neu (c-erbB2) in endometrial cancers: correlation with overall survival","volume":"55","author":"Saffari","year":"1995","journal-title":"Cancer Res"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/ijgc-00009577-200609000-00027","article-title":"HER-2\/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications","volume":"16","author":"Villella","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijgo.2008.04.008","article-title":"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2\/neu","volume":"102","author":"Santin","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5858\/2007-131-18-ASOCCO","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"131","author":"Wolff","year":"2007","journal-title":"Arch Pathol Lab Med"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"138","author":"Wolff","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human Epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R30-20250802","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"suppl 1","key":"R35-20250802","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.6004\/jnccn.2014.0209","article-title":"Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute","volume":"12","author":"Kamal","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ajcp\/aqy166","article-title":"Impact of specimen type and specimen number on HER2 status in gastroesophageal junction and gastric adenocarcinoma","volume":"151","author":"Huber","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Halle","year":"2018","journal-title":"Br J Cancer"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"100561","DOI":"10.1016\/j.gore.2020.100561","article-title":"Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression","volume":"32","author":"Quddus","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","article-title":"Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity","volume":"152","author":"Muller","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","article-title":"Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer","volume":"53","author":"Wakatsuki","year":"2018","journal-title":"J Gastroenterol"},{"key":"R41-20250802","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","article-title":"Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2","volume":"10","author":"Gennari","year":"2004","journal-title":"Clin Cancer Res"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:05:13Z","timestamp":1754161513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000711","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}